Traders Sell Shares of Pfizer (PFE) on Strength (PFE)

Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading on Friday. $88.20 million flowed into the stock on the tick-up and $190.63 million flowed out of the stock on the tick-down, for a money net flow of $102.43 million out of the stock. Of all equities tracked, Pfizer had the 11th highest net out-flow for the day. Pfizer traded up $0.55 for the day and closed at $36.26

PFE has been the subject of a number of research analyst reports. UBS Group set a $40.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, December 6th. BMO Capital Markets reaffirmed a “buy” rating and set a $39.00 price objective on shares of Pfizer in a research note on Friday, November 10th. Sanford C. Bernstein set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, January 30th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective for the company in a research note on Wednesday, January 17th. Finally, Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price objective for the company in a research note on Thursday, November 23rd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and an average price target of $39.45.

The company has a market capitalization of $216,140.00, a price-to-earnings ratio of 10.30, a price-to-earnings-growth ratio of 1.99 and a beta of 0.94. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.06. The company had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The firm’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.47 EPS. analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a $0.34 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.75%. Pfizer’s dividend payout ratio is currently 38.64%.

Pfizer declared that its Board of Directors has authorized a share repurchase plan on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.

In related news, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the transaction, the insider now owns 103,458 shares in the company, valued at $3,827,946. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares in the company, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. 0.06% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Earnest Partners LLC bought a new stake in Pfizer during the fourth quarter worth approximately $105,000. Shine Investment Advisory Services Inc. bought a new stake in Pfizer during the second quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware bought a new stake in Pfizer during the second quarter worth approximately $103,000. First Dallas Securities Inc. bought a new stake in Pfizer during the fourth quarter worth approximately $118,000. Finally, Woodard & Co. Asset Management Group Inc. ADV bought a new stake in Pfizer during the fourth quarter worth approximately $118,000. Hedge funds and other institutional investors own 70.06% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2018/02/16/traders-sell-shares-of-pfizer-pfe-on-strength-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply